Xention appoints new director of business development
This article was originally published in Scrip
Executive Summary
The UK biopharmaceutical company Xention has named Dr Calum Graham director of business development. He joins from GlaxoSmithKline, where he has served as director of scientific licensing in worldwide business development for the past six years. Before that, he held senior roles in a number of other departments at GSK, including head of disease strategy in the Neurology & GI Centre of Excellence for Drug Discovery (CEDD) and assistant director in the anti-infective therapeutic unit.